CN112870277B - 一种防治复发性流产的中药组合物 - Google Patents
一种防治复发性流产的中药组合物 Download PDFInfo
- Publication number
- CN112870277B CN112870277B CN202110229929.1A CN202110229929A CN112870277B CN 112870277 B CN112870277 B CN 112870277B CN 202110229929 A CN202110229929 A CN 202110229929A CN 112870277 B CN112870277 B CN 112870277B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 208000008899 Habitual abortion Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 7
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- 241000123589 Dipsacus Species 0.000 claims abstract description 6
- 241000488974 Loranthus Species 0.000 claims abstract description 5
- 230000003071 parasitic effect Effects 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 240000001398 Typha domingensis Species 0.000 claims abstract 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 29
- 208000000995 spontaneous abortion Diseases 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 6
- 241000913745 Spatholobus Species 0.000 claims description 5
- 240000007371 Cuscuta campestris Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000035935 pregnancy Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 208000015994 miscarriage Diseases 0.000 description 20
- 230000002265 prevention Effects 0.000 description 20
- 208000011580 syndromic disease Diseases 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 206010067484 Adverse reaction Diseases 0.000 description 12
- 206010046788 Uterine haemorrhage Diseases 0.000 description 12
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 12
- 230000006838 adverse reaction Effects 0.000 description 12
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003154 D dimer Substances 0.000 description 9
- 206010000210 abortion Diseases 0.000 description 9
- 231100000176 abortion Toxicity 0.000 description 9
- 108010052295 fibrin fragment D Proteins 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 206010057071 Rectal tenesmus Diseases 0.000 description 4
- 241000233948 Typha Species 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 208000012271 tenesmus Diseases 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000035010 Term birth Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010051459 Imminent abortion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000316342 Taxillus Species 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及中药复方技术领域，具体涉及一种防治复发性流产的中药组合物。所述用于防治复发性流产的中药组合物由以下药用原料制成：菟丝子25‑35份、桑寄生10‑20份、续断10‑20份、炒蒲黄8‑14份、人参8‑13份、陈皮7‑12份以及鸡血藤20‑35份，所述中药组合物的安全性高、便于提高安胎成功率，并可通过与其他药物联以提高临床疗效。
Description
技术领域
本发明涉及中药复方技术领域，尤其涉及一种防治复发性流产的中药组合物。
背景技术
一对夫妻多次发生的自然流产，为复发性流产(RSA)。我国将3次或3次以上在妊娠28周之前的胎儿丢失定义为RSA,同时提出应重视连续发生2次的流产并予评估。RSA在生育期女性中发病率约5%，是最常见的妊娠期并发症之一，其病因复杂，最近的生殖免疫研究表明，RSA的病因50%以上与免疫功能紊乱有关，与引起自身免疫性疾病的抗磷脂综合征（APS）关系最为密切。
抗磷脂综合征主要临床表现为复发性流产、动静脉血栓形成和血小板减少等，可产生抗磷脂抗体，包括狼疮抗凝物质（LA）、抗心磷脂抗体ACA、抗β2-糖蛋白Ⅰ抗体（anti-β2-GPⅠIgG）。所以磷脂抗体通过攻击供应胚胎营养的微循环血管，从而导致胚胎就因营养供应不足而死亡。
目前，抗磷脂综合征是唯一被证实与不良妊娠结局相关的导致血栓形成倾向的自身免疫型因素，也被认为是RSA病因中治疗最有意义的。APS的病理基础主要与血小板活化以及内皮细胞受损等有关。随着免疫性复发性流产日益受到广泛关注，西医学研究指出免疫性复发性流产的主要病因为血栓前状态，主要免疫学诊断为抗磷脂综合征，主要临床特征为动静脉血栓形成、病理妊娠(妊娠早期流产和中晚期死胎)和血小板计数减少。受APS影响的女性会产生一种或多种针对磷脂的抗磷脂抗体（aPL），是存在于滋养层中并在组织重塑时暴露于外表面抗体，还产生分子诸如狼疮抗凝蛋白、心磷脂、β2糖蛋白Ⅰ（β2GPI）、凝血酶原、膜联蛋白等。APS通常在患者怀孕和流产时首次出现，是主要的产科并发症，反复引发自然流产。机制方面，有人提出aPL诱导促凝表型,炎症似乎是导致APS患者胎盘损伤的必要因素，因为并非所有APS患者的妊娠都会导致并发症。早期的研究表明APS患者炎性反应异常，但是其具体机制尚不清楚。
目前，临床上对患有APS的RSA患者的治疗主要关注于如何预防血栓的形成。一般临床常用低分子肝素或阿司匹林治疗。然而，抗凝治疗只对部分患者有效，疗效较差且副作用较多。
发明内容
为解决上述技术问题，本发明的目的在于提供一种用于防治复发性流产的中药组合物，所述中药组合物的安全性高、便于提高安胎成功率，并可通过与其他药物联以提高临床疗效。
为达到上述技术效果，本发明采用了以下技术方案：
一种防治复发性流产的中药组合物，由以下药用原料制成：菟丝子、桑寄生、续断、炒蒲黄、人参、陈皮以及鸡血藤。
进一步地，所述防治复发性流产的中药组合物，由以下质量份数的药用原料制成：菟丝子25-35份、桑寄生10-20份、续断10-20份、炒蒲黄8-14份、人参8-13份、陈皮7-12份以及鸡血藤20-35份。
进一步地，所述防治复发性流产的中药组合物，由以下质量份数的药用原料制成：菟丝子30份、桑寄生15份、续断15份、炒蒲黄10份、人参10份、陈皮10份以及鸡血藤30份。
进一步地，所述防治复发性流产的中药组合物，其特征在于：所述中药组合物中还包括若干药学上可接受的辅料。
进一步地，所述防治复发性流产的中药组合物，其特征在于：所述中药组合物为汤剂、丸剂、片剂、胶囊剂、颗粒剂或者注射剂。
进一步地，所述汤剂的制备方法为：取配方中的中药饮片加水浸泡0.5 h-1h后，再连续煎煮3-5次，合并各次煎煮的滤液，得到该中药组合物的汤剂。
与现有技术相比，本发明的有益效果为：
本发明提供的一种用于防治复发性流产的中药组合物的以“补肾活血”为法，以菟丝子补肾益精，固冲安胎作为君药；桑寄生、续断补肝肾、固冲任，使胎气强壮；以炒蒲黄、鸡血藤以活血化瘀；加人参、陈皮以补气行气助活血之效。并通过临床验证，能够对抗磷脂综合征引起的复发性流产具有良好的防治效果，且该药物组合物的安全性高、制备方法简单、便于提高安胎成功率，并可通过与其他药物联以提高临床疗效，降低单一药物使用的不良反应发生率。
具体实施方式
以下实施例仅用于更加清楚地说明本发明的技术方案，因此只作为示例，而不能以此来限制本发明的保护范围。
实施例1
汤剂的制备：
配方：菟丝子30g、桑寄生15g、续断15g、炒蒲黄10g、人参10g、陈皮10g以及鸡血藤30g
制备方法：取配方中的中药饮片加水浸泡0.5 h-1h后，再连续煎煮3-5次，合并各次煎煮的滤液，将合并后的滤液浓缩至1200 ml，得到该中药组合物的汤剂。
实施例2
将上述实施例1中制备得到的汤剂进行浓缩后，加入一定的药用辅料，将其分别制备为丸剂、片剂、胶囊剂、颗粒剂以及注射剂。
实施例3
1资料与方法
1.1观察资料
将2017年3月-2019年12月在深圳市妇幼保健院中医科住院部住院安胎的先兆流产患者部分纳入临床实验，共纳入符合肾虚血瘀型抗磷脂综合征所致复发性流产患者138例，年龄在25-48岁之间，平均年龄为33.7岁；其中，既往自然流产次数2-8次，其中自然流产2次者82例，3次者37例，4次及以上者19例，平均流产次数2.64次。将上述所有患者随机分为观察组和对照组，组别间在年龄、孕次、自然流产次数等基线资料上差异无统计学意义（P>0.05），具有可比性。其中，观察组和对照组的具体资料见表1。
表1 观察组和对照组患者一般情况基线资料( 
)
1.2纳入与排除标准
1.2.1纳入标准包括：
①符合APS所致复发性流产诊断标准，辨证属肾虚血瘀证；
②此次受孕为自然受孕或IVF-ET；
③年龄在20-48岁；
④卵泡期FSH≤10mIU/L；
⑤能够接受中药或免疫抑制剂治疗者。
其中，标准①中所述的APS所致复发性流产的诊断标准包括条件a、b以及c，具体地：
a.复发性流产（RSA）西医诊断标准：具有连续2次或2次以上自然流产；
b.抗磷脂综合征诊断标准：至少包括复发性流产或血栓栓塞中的一项临床症状以及同时具有一项抗磷脂抗体阳性实验室指标（抗磷脂抗体检测指标为：抗心磷脂抗体(ACA)；抗β2GP-1 抗体；狼疮抗凝因子(LAC)。阳性诊断标准是指出现2 次以上抗磷脂抗体阳性,其间隔时间6周或以上）。
c.中医诊断标准（肾虚血瘀型免疫相关复发性流产）包括：
（a.）主症：①阴道少量流血；②小腹疼痛或坠胀；③腰酸胀痛；
（b.）次症：①精神倦怠；②头晕耳鸣；③夜尿频多；④眼眶暗黑或面部暗斑；⑤曾屡堕胎；
（c.）舌脉：舌暗，边尖有瘀点，苔薄白，脉沉滑或弦滑。
其中，具备以上主症2项以及次症2项或以上，结合舌脉，即可辨证为本证。
1.2.2排除标准包含：
①合并有子宫结构异常、先天性血栓前状态、内分泌功能异常；
②有严重药物过敏史者；
②有遗传因素如夫妇一方存在染色体异常所致复发性流产；
④有感染因素所致复发性流产。
2研究方法
2.1临床实验方法
观察组：服用实施例1中制备得到汤剂（用法用量为：每次一剂200 ml，一日二次，口服），联用低分子肝素钙（速碧林，葛兰素史克生产，批号：0.4ml：4100AXaIU 国药准字J20090005）皮下注射，一日一次。
对照组：单用低分子肝素钙进行治疗（速碧林，葛兰素史克生产，批号： 0.4ml：4100AXaIU 国药准字J20090005），皮下注射，一日一次。
2.2观察指标：
（1）主要观察指标
妊娠结局情况，包括孕12周安胎成功率、足月产、早产胎儿存活、流产、早产胎儿死亡等情况，结果见表3和表4；
（2）次要观察指标
①中医症候情况：对照治疗前后中医症候积分情况，结果见表5；
②免疫检查及凝血功能检测：治疗前后检测抗磷脂抗体及凝血功能：抗磷脂抗体指标包括狼疮抗凝物质（LA）、抗心磷脂抗体ACA、抗β2-糖蛋白Ⅰ抗体（anti-β2-GPⅠIgG）；凝血纤溶指标包括：超敏D-二聚体（D-D）、血浆凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、纤维蛋白原（FIB），结果见表6和表7。
2.3疗效评价方法：
2.3.1妊娠结局情况评定
评定安胎成功指标分成两部分：孕早期安胎成功标准以孕12周NT彩超结果提示宫内孕正常为孕早期安胎成功指标；孕晚期安胎成功标准以妊娠成功率=（足月产+早产胎儿存活）/（足月产+早产胎儿存活+流产+早产胎儿死亡）为孕晚期安胎成功指标。
2.3.2临床疗效评定标准参照中药新药临床研究指导原则修改制定
(1)痊愈：治疗后 5 天内阴道流血停止,小腹疼痛及腰酸胀痛等症消失，凝血-纤溶指标恢复正常、D-二聚体降至正常,妇科彩超检查示子宫大小、胚胎发育情况与孕周相符，证候积分减少大于95%，孕12 周时胎儿发育正常；
(2)显效：治疗 7 天阴道流血停止,小腹疼痛及腰酸胀痛等明显减轻，凝血-纤溶指标大部分改善、D-二聚体较前减轻,妇科彩超检查示子宫大小、胚胎发育情况与孕周相符，证候积分减少70%-95%，孕12 周时胎儿发育正常；
(3)有效：治疗后 10 天阴道流血停止,小腹隐痛及腰酸胀痛等症有所减轻, 凝血-纤溶指标有所改善、D-二聚体较前减轻,妇科彩超检查示子宫大小、胚胎发育情况与孕周基本相符，证候积分减少 30%-70%；
(4)无效：治疗后阴道流血超过 10 天未止,小腹疼痛及腰酸胀痛等症无减轻或有加重, 凝血-纤溶指标未改善或恶化、D-二聚体未减轻或升高,妇科彩超检查示子宫大小、胚胎发育情况与孕周基本相符或小于孕周,胚胎发育不良或停止发育,甚至发生难免流产证候积分减少小于 30%。
2.3.3中医疗效评定标准
中医证候疗效评价：根据症状量表评分，分别在治疗前及治疗后（孕12周）各评价一次，症状量表详见表2。
表2 症状量表
| 主症 | 0分 | 2分 | 3分 | 6分 |
| 自然堕胎史 | 无 | 2次 | 3次 | >> 4次 |
| 阴道出血量 | 无 | 时有时无，点滴而下 | 淋漓难净，量少 | 持续不净需用垫纸 |
| 出血色质 | 无 | 色淡紫，质薄 | 色淡暗，质清稀 | 色淡黯，如黑豆汁 |
| 小腹疼痛或坠胀 | 无 | 疼痛或坠胀时有时无 | 疼痛或坠胀持续存在 | 疼痛伴坠胀持续存在 |
| 腰酸胀痛 | 无 | 时有时无 | 不持续存在 | 持续存在 |
| 次症 | 0分 | 1分 | 2分 | 3分 |
| 两膝酸软 | 无 | 时有时无 | 持续存在 | 不欲行走 |
| 神疲肢倦 | 无 | 时有时无 | 持续存在 | 懒于行动 |
| 头晕耳鸣 | 无 | 偶有出现 | 时有时无 | 频繁出现 |
| 夜尿频多 | 无 | 1次 | 2次 | >> 3次 |
| 眼眶暗黑或面部暗斑 | 无 | 暗淡 | 灰黑 | 暗黑 |
其中，病情分度：中医症候积分积分≤15分为轻度，16-30分为中度，≥31分为重度。
根据《中药新药临床研究指导原则》修改制定（疗效指数(n)＝[(治疗前积分—治疗后积分)/治疗前积分]×100%）：
痊愈：治疗后各症状消失，证候积分值减少≥95%；
显效：治疗后各症状明显减轻，证候积分值减少≥70%，<95%；
有效：治疗后各症状有所减轻，证候积分值减少≥30%，<70%；
无效：治疗后各症状无减轻或有加重，证候积分值减少<30%。
2.3.4安全性观察指标
治疗前后分别检测四测及血、尿常规、肝功能、肾功能、心电图;记录用药后不良反应：临床上需密切观察受试者可能出现的不良反应，如阴道出血突然增多、肝功能异常、过敏反应、血小板减少、骨质疏松等,并详细记录,评估与临床用药的相关性，结果见表8。
2.4统计学方法
采用SPSS 25.0进行数据统计分析，计量资料以表示，组间比较采用成组t 检验,治疗前后比较采用配对t检验；计数资料用百分比表示，组间比较采用卡方检验，p<0.05表示差异有统计学意义，P<0.01表示差异有显著统计学意义。
3.研究结果
3.1 观察组和对照组RSA患者妊娠结局比较，结果见表3
表3 观察组和对照组RSA患者妊娠结局比较（例）
治疗后，观察组孕早期安胎成功率为89.86%，孕晚期安胎成功率为84.06%；对照组孕早期安胎成功率为68.12%，孕晚期安胎成功率为57.97%。观察组安胎成功率显著高于对照组，差异有统计学意义（P<0.01）。
3.2观察组和对照组RSA患者临床疗效比较
治疗后，观察组有效率91.30%，对照组有效率71.01%，观察组总有效率显著高于对照组，差异有统计学意义（P<0.01），结果见表4。
表4 观察组和对照组治疗后临床疗效分级比较（例）
3.3 观察组和对照组治疗后中医症候改善情况比较
观察组治疗前后中医证候积分经配对t检验，差异有统计学意义(P<0.01),对照组治疗前后的差异有统计学意义(P<0.01),提示观察组和对照组治疗均有疗效。治疗后观察组干预效果优于对照组，差异有统计学意义(P<0.01),提示安子调冲汤联合肝素在改善中医证候上优于单独使用肝素。结果见表5。
表5 观察组和对照组治疗后症候积分改善情况比较（
）
3.4 观察组和对照组RSA患者抗磷脂抗体转阴率比较
观察组治疗后抗磷脂抗体转阴率为91.30%，对照组治疗后抗磷脂抗体转阴率为75.36%，观察组和对照组治疗后抗体转阴情况经检验，差异有统计学意义(P<0.05)。结果见表6。
表6 观察组和对照组RSA患者抗磷脂抗体转阴率比较（例）
| 组别 | n | ACA+ | LA+ | Anti-β2-GPⅠIgG+ | 抗体转阴 | 转阴率% |  | <i>P</i> |
| 观察组 | 69 | 31 | 18 | 20 | 63 | 91.30 | 6.313 | 0.012 |
| 对照组 | 69 | 30 | 21 | 18 | 52 | 75.36 |
3.5 观察组和对照组治疗前后凝血-纤溶指标比较
经治疗后，经配对t检验，观察组与对照组凝血-纤溶指标均较前改善，PT、APTT较前增加，观察组升高程度较对照组更大，差异有统计学意义（P<0.05），FIB、D-D较前下降，观察组较对照组降低程度更大，差异有统计学意义（P<0.01），提示观察组和对照组治疗后高凝状态均有改善，且治疗后观察组干预效果优于对照组。结果见表7。
表7 观察组和对照组治疗前后凝血-纤溶指标比较
注：P为治疗后观察组与对照组组间比较。
3.6 观察组和对照组治疗后不良反应比较
观察组和对照组治疗后出现不良反应，诸如阴道出血突然增多、肝功能异常、过敏反应、血小板减少、骨质疏松等。观察组出现1例阴道出血突然增多、1例肝功能异常，对照组出现3例阴道流血增多，4例肝功能异常，5例出现皮肤过敏反应，观察组和对照组均未见血小板减少及骨质疏松。观察组不良反应发生率为2.90%，对照组不良反应发生率为17.39%，可知观察组较对照组发生不良反应少、安全性更高。详见表8。
表8 观察组和对照组治疗后不良反应比较
妊娠结局比较方面，观察组孕早期安胎成功率为89.86%，孕晚期安胎成功率为84.06%；对照组孕早期安胎成功率为68.12%，孕晚期安胎成功率为57.97%，观察组安胎成功率显著高于对照组（P<0.01）。临床疗效比较方面，观察组有效率91.30%，对照组有效率71.01%，观察组总有效率显著高于对照组（P<0.01）；中医症候改善情况，治疗后观察组干预效果优于对照组(P<0.01)，尤其在改善阴道流血、小腹隐痛及腰酸胀痛症状方面由于对照组。观察组治疗后抗磷脂抗体转阴率为91.30%，对照组治疗后抗磷脂抗体转阴率为75.36%，观察组治疗后抗体转阴高于对照组(P<0.05)。同时，还发现观察组6例抗体未转阴者复查D-二聚体仍偏高，且均发生早期流产。观察组和对照组凝血-纤溶指标均较治疗前改善，PT、APTT较前增加，观察组升高程度较对照组更大，差异有统计学意义（P<0.05），FIB、D-D较前下降，观察组较对照组降低程度更大（P<0.01），提示观察组和对照组治疗后高凝状态均有改善，且治疗后观察组干预效果优于对照组。安全性方面，观察组出现1例阴道出血突然增多、1例肝功能异常，不良反应发生率为2.90%，对照组出现3例阴道流血增多，4例肝功能异常，5例出现皮肤过敏反应，不良反应发生率为17.39%，观察组较对照组发生不良反应少、安全性更高。
综上所述，安子调冲汤联合低分子肝素钙治疗复发性流产合并抗磷脂综合征疗效显著，可提高安胎成功率和临床疗效，降低中医症候积分，增加抗磷脂抗体转阴率，改善凝血-纤溶指标，且安全性高，应尽早应用。
以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的宗旨和范围，其均应涵盖在本发明的权利要求范围当中。本发明未详细描述的技术、形状、构造部分均为公知技术。
Claims (4)
1.一种防治复发性流产的中药组合物，其特征在于，由以下质量份数的药用原料制成：菟丝子30份、桑寄生15份、续断15份、炒蒲黄10份、人参10份、陈皮10份以及鸡血藤30份。
2.如权利要求1所述的一种防治复发性流产的中药组合物，其特征在于：所述中药组合物中还包括若干药学上可接受的辅料。
3.如权利要求1所述的一种防治复发性流产的中药组合物，其特征在于：所述中药组合物为汤剂、丸剂、片剂、胶囊剂、颗粒剂或者注射剂。
4.如权利要求3所述的一种防治复发性流产的中药组合物的制备方法，其特征在于，所述汤剂的制备方法为：取配方中的中药饮片加水浸泡0.5 h-1h后，再连续煎煮3-5次，合并各次煎煮的滤液，得到该中药组合物的汤剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110229929.1A CN112870277B (zh) | 2021-03-02 | 2021-03-02 | 一种防治复发性流产的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110229929.1A CN112870277B (zh) | 2021-03-02 | 2021-03-02 | 一种防治复发性流产的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112870277A CN112870277A (zh) | 2021-06-01 |
| CN112870277B true CN112870277B (zh) | 2022-05-10 |
Family
ID=76055211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110229929.1A Active CN112870277B (zh) | 2021-03-02 | 2021-03-02 | 一种防治复发性流产的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112870277B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329892A (zh) * | 2020-04-10 | 2020-06-26 | 上海市第一妇婴保健院 | 一种治疗复发性流产合并抗磷脂综合征的中药组合物及其应用 |
-
2021
- 2021-03-02 CN CN202110229929.1A patent/CN112870277B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329892A (zh) * | 2020-04-10 | 2020-06-26 | 上海市第一妇婴保健院 | 一种治疗复发性流产合并抗磷脂综合征的中药组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112870277A (zh) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sajith et al. | Incidence of pregnancy induced hypertension and prescription pattern of antihypertensive drugs in pregnancy | |
| Stenlund et al. | Induction of labor with mifepristone,-A randomized, double-blind study versus placebo | |
| Surbek et al. | A double-blind comparison of the safety and efficacy of intravaginal misoprostol and prostaglandin E2 to induce labor | |
| CN112870277B (zh) | 一种防治复发性流产的中药组合物 | |
| CN110960642B (zh) | 滋肾育胎丸在制备预防子痫前期的药物中的应用 | |
| Wang et al. | Clinical effects of integrated traditional chinese and western medicine in treating severe preeclampsia and its influence on maternal and infant outcomes after cesarean section under combined lumbar and epidural anesthesia | |
| Ventoskovskiy et al. | Homoeopathy as a practical alternative to traditional obstetric methods | |
| Page | The effect of eclamptic blood upon the urinary output and blood pressure of human recipients | |
| MOLONEY et al. | LEUKEMIA IN PREGNANCY: WITH REPORT OF A CASE | |
| CN104645297B (zh) | 一种温宫助孕的中药组合物及其制剂制备方法 | |
| CN113521175A (zh) | 一种中药组合物在制备治疗男性畸形精子症的药物中的新用途 | |
| Sultana et al. | Usefulness of polyherbal Unani formulation for cervical ripening and induction of labour: a uncontrolled study | |
| El-Qarmalawi et al. | A comparative randomized study of oral prostaglandin E2 (PGE2) tablets and intravenous oxytocin in induction of labor in patients with premature rupture of membranes before 37 weeks of pregnancy | |
| RU2359687C1 (ru) | Способ неоперативного лечения миомы матки с учетом нового взгляда на ее этиопатогенез | |
| CN108159148A (zh) | 一种桂枝茯苓丸及制备方法和应用 | |
| CN116803405B (zh) | 一种用于防治先兆流产或复发性流产的中药组合物及其应用 | |
| HARELL-STEINBERG et al. | Observations on hypoparathyroidism. I. Exfoliative dermatitis as the presenting sign of hypoparathyroidism: a case report | |
| CN113018367B (zh) | 一种具有治疗薄型子宫内膜性月经量少的中药组合物及其制备方法与应用 | |
| DUFFY et al. | Suppression of lactation by testosterone | |
| Prabha et al. | A Comparative Study of the Efficacy of Labetalol and Nifedipine in Preeclampsia | |
| Liu et al. | Clinical Efficacy and Nursing Efficiency Analysis of Jiuwei Zhusheng Decoction in Promoting Cervical Ripening in the Perinatal Midwifery Holistic Care | |
| Zhang et al. | Analysis of a Study of Nifedipine Sustained-release Tablets Combined with Magnesium Sulfate in the Treatment of Hypertension during Pregnancy | |
| مبارکی et al. | Comparison of the effect of vaginal misoprostol alone and in combination with evening primrose capsules on the course of labor in pregnant women candidates for termination of pregnancy | |
| CN118267427A (zh) | 一种治疗封闭抗体异常的中药组合物及其药物制剂与应用 | |
| RU2464038C1 (ru) | Сбор лекарственных растений для профилактики первичной плацентарной недостаточности у пациенток с проявлением местного иммунодефицита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |